Abstract
Chronic active antibody-mediated rejection (caAMR) caused by de novo donor-specific antibodies (dnDSA) is the main risk factor of late allograft loss in kidney transplantation. The treatment remains difficult due to the lack of effective methods. Through comprehensive management pre and post kidney transplantation, which starts from the prevention of dnDSA generation, periodical monitoring of dnDSA, to timely implement of pathological diagnosis and early initiation of synthetical treatment, it will be beneficial to the prevention and treatment of caAMR and ultimately improve the long-term survival of the renal graft.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
